Cancer immunotherapy, also called biologic therapy, which can predominantly be classed as a form of targeted therapy, It is designed to stimulate the body's immune system to attack tumours.

The global Cancer Immunotherapies market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Cancer Immunotherapies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Cancer Immunotherapies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Cancer Immunotherapies include Amgen, AstraZeneca, Roche, Bristol-Myers Squibb, Bayer, Merck, ARMO BioSciences (Eli Lilly), Novartis and Pfizer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Cancer Immunotherapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Immunotherapies.

Report Scope

The Cancer Immunotherapies market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Immunotherapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cancer Immunotherapies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Cancer Immunotherapies Market Report

Report Metric	Details
Report Name	Cancer Immunotherapies Market
Segment by Type	Monoclonal Antibodies (MABs) Cancer Vaccines Immunomodulators Adoptive Cell transfer Checkpoint Inhibitors
Segment by Application	Breast Cancer Leukemia Lymphoma Melanoma Colorectal Cancer Non-Small Cell Lung Cancer
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Amgen, AstraZeneca, Roche, Bristol-Myers Squibb, Bayer, Merck, ARMO BioSciences (Eli Lilly), Novartis, Pfizer, Johnson & Johnson, AbbVie, Gilead Sciences
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cancer Immunotherapies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cancer Immunotherapies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Cancer Immunotherapies Market report?

Ans: The main players in the Cancer Immunotherapies Market are Amgen, AstraZeneca, Roche, Bristol-Myers Squibb, Bayer, Merck, ARMO BioSciences (Eli Lilly), Novartis, Pfizer, Johnson & Johnson, AbbVie, Gilead Sciences

What are the Application segmentation covered in the Cancer Immunotherapies Market report?

Ans: The Applications covered in the Cancer Immunotherapies Market report are Breast Cancer, Leukemia, Lymphoma, Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer

What are the Type segmentation covered in the Cancer Immunotherapies Market report?

Ans: The Types covered in the Cancer Immunotherapies Market report are Monoclonal Antibodies (MABs), Cancer Vaccines, Immunomodulators, Adoptive Cell transfer, Checkpoint Inhibitors

1 Cancer Immunotherapies Market Overview

1.1 Product Overview and Scope of Cancer Immunotherapies

1.2 Cancer Immunotherapies Segment by Type

1.2.1 Global Cancer Immunotherapies Market Value Comparison by Type (2024-2030)

1.2.2 Monoclonal Antibodies (MABs)

1.2.3 Cancer Vaccines

1.2.4 Immunomodulators

1.2.5 Adoptive Cell transfer

1.2.6 Checkpoint Inhibitors

1.3 Cancer Immunotherapies Segment by Application

1.3.1 Global Cancer Immunotherapies Market Value by Application: (2024-2030)

1.3.2 Breast Cancer

1.3.3 Leukemia

1.3.4 Lymphoma

1.3.5 Melanoma

1.3.6 Colorectal Cancer

1.3.7 Non-Small Cell Lung Cancer

1.4 Global Cancer Immunotherapies Market Size Estimates and Forecasts

1.4.1 Global Cancer Immunotherapies Revenue 2019-2030

1.4.2 Global Cancer Immunotherapies Sales 2019-2030

1.4.3 Global Cancer Immunotherapies Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Cancer Immunotherapies Market Competition by Manufacturers

2.1 Global Cancer Immunotherapies Sales Market Share by Manufacturers (2019-2024)

2.2 Global Cancer Immunotherapies Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Cancer Immunotherapies Average Price by Manufacturers (2019-2024)

2.4 Global Cancer Immunotherapies Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Cancer Immunotherapies, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Cancer Immunotherapies, Product Type & Application

2.7 Cancer Immunotherapies Market Competitive Situation and Trends

2.7.1 Cancer Immunotherapies Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Cancer Immunotherapies Players Market Share by Revenue

2.7.3 Global Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Cancer Immunotherapies Retrospective Market Scenario by Region

3.1 Global Cancer Immunotherapies Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Cancer Immunotherapies Global Cancer Immunotherapies Sales by Region: 2019-2030

3.2.1 Global Cancer Immunotherapies Sales by Region: 2019-2024

3.2.2 Global Cancer Immunotherapies Sales by Region: 2025-2030

3.3 Global Cancer Immunotherapies Global Cancer Immunotherapies Revenue by Region: 2019-2030

3.3.1 Global Cancer Immunotherapies Revenue by Region: 2019-2024

3.3.2 Global Cancer Immunotherapies Revenue by Region: 2025-2030

3.4 North America Cancer Immunotherapies Market Facts & Figures by Country

3.4.1 North America Cancer Immunotherapies Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Cancer Immunotherapies Sales by Country (2019-2030)

3.4.3 North America Cancer Immunotherapies Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Cancer Immunotherapies Market Facts & Figures by Country

3.5.1 Europe Cancer Immunotherapies Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Cancer Immunotherapies Sales by Country (2019-2030)

3.5.3 Europe Cancer Immunotherapies Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Cancer Immunotherapies Market Facts & Figures by Country

3.6.1 Asia Pacific Cancer Immunotherapies Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Cancer Immunotherapies Sales by Country (2019-2030)

3.6.3 Asia Pacific Cancer Immunotherapies Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Cancer Immunotherapies Market Facts & Figures by Country

3.7.1 Latin America Cancer Immunotherapies Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Cancer Immunotherapies Sales by Country (2019-2030)

3.7.3 Latin America Cancer Immunotherapies Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Cancer Immunotherapies Market Facts & Figures by Country

3.8.1 Middle East and Africa Cancer Immunotherapies Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Cancer Immunotherapies Sales by Country (2019-2030)

3.8.3 Middle East and Africa Cancer Immunotherapies Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Cancer Immunotherapies Sales by Type (2019-2030)

4.1.1 Global Cancer Immunotherapies Sales by Type (2019-2024)

4.1.2 Global Cancer Immunotherapies Sales by Type (2025-2030)

4.1.3 Global Cancer Immunotherapies Sales Market Share by Type (2019-2030)

4.2 Global Cancer Immunotherapies Revenue by Type (2019-2030)

4.2.1 Global Cancer Immunotherapies Revenue by Type (2019-2024)

4.2.2 Global Cancer Immunotherapies Revenue by Type (2025-2030)

4.2.3 Global Cancer Immunotherapies Revenue Market Share by Type (2019-2030)

4.3 Global Cancer Immunotherapies Price by Type (2019-2030)

5 Segment by Application

5.1 Global Cancer Immunotherapies Sales by Application (2019-2030)

5.1.1 Global Cancer Immunotherapies Sales by Application (2019-2024)

5.1.2 Global Cancer Immunotherapies Sales by Application (2025-2030)

5.1.3 Global Cancer Immunotherapies Sales Market Share by Application (2019-2030)

5.2 Global Cancer Immunotherapies Revenue by Application (2019-2030)

5.2.1 Global Cancer Immunotherapies Revenue by Application (2019-2024)

5.2.2 Global Cancer Immunotherapies Revenue by Application (2025-2030)

5.2.3 Global Cancer Immunotherapies Revenue Market Share by Application (2019-2030)

5.3 Global Cancer Immunotherapies Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Amgen

6.1.1 Amgen Corporation Information

6.1.2 Amgen Description and Business Overview

6.1.3 Amgen Cancer Immunotherapies Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Amgen Cancer Immunotherapies Product Portfolio

6.1.5 Amgen Recent Developments/Updates

6.2 AstraZeneca

6.2.1 AstraZeneca Corporation Information

6.2.2 AstraZeneca Description and Business Overview

6.2.3 AstraZeneca Cancer Immunotherapies Sales, Revenue and Gross Margin (2019-2024)

6.2.4 AstraZeneca Cancer Immunotherapies Product Portfolio

6.2.5 AstraZeneca Recent Developments/Updates

6.3 Roche

6.3.1 Roche Corporation Information

6.3.2 Roche Description and Business Overview

6.3.3 Roche Cancer Immunotherapies Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Roche Cancer Immunotherapies Product Portfolio

6.3.5 Roche Recent Developments/Updates

6.4 Bristol-Myers Squibb

6.4.1 Bristol-Myers Squibb Corporation Information

6.4.2 Bristol-Myers Squibb Description and Business Overview

6.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Bristol-Myers Squibb Cancer Immunotherapies Product Portfolio

6.4.5 Bristol-Myers Squibb Recent Developments/Updates

6.5 Bayer

6.5.1 Bayer Corporation Information

6.5.2 Bayer Description and Business Overview

6.5.3 Bayer Cancer Immunotherapies Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Bayer Cancer Immunotherapies Product Portfolio

6.5.5 Bayer Recent Developments/Updates

6.6 Merck

6.6.1 Merck Corporation Information

6.6.2 Merck Description and Business Overview

6.6.3 Merck Cancer Immunotherapies Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Merck Cancer Immunotherapies Product Portfolio

6.6.5 Merck Recent Developments/Updates

6.7 ARMO BioSciences (Eli Lilly)

6.6.1 ARMO BioSciences (Eli Lilly) Corporation Information

6.6.2 ARMO BioSciences (Eli Lilly) Description and Business Overview

6.6.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue and Gross Margin (2019-2024)

6.4.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Portfolio

6.7.5 ARMO BioSciences (Eli Lilly) Recent Developments/Updates

6.8 Novartis

6.8.1 Novartis Corporation Information

6.8.2 Novartis Description and Business Overview

6.8.3 Novartis Cancer Immunotherapies Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Novartis Cancer Immunotherapies Product Portfolio

6.8.5 Novartis Recent Developments/Updates

6.9 Pfizer

6.9.1 Pfizer Corporation Information

6.9.2 Pfizer Description and Business Overview

6.9.3 Pfizer Cancer Immunotherapies Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Pfizer Cancer Immunotherapies Product Portfolio

6.9.5 Pfizer Recent Developments/Updates

6.10 Johnson & Johnson

6.10.1 Johnson & Johnson Corporation Information

6.10.2 Johnson & Johnson Description and Business Overview

6.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Johnson & Johnson Cancer Immunotherapies Product Portfolio

6.10.5 Johnson & Johnson Recent Developments/Updates

6.11 AbbVie

6.11.1 AbbVie Corporation Information

6.11.2 AbbVie Cancer Immunotherapies Description and Business Overview

6.11.3 AbbVie Cancer Immunotherapies Sales, Revenue and Gross Margin (2019-2024)

6.11.4 AbbVie Cancer Immunotherapies Product Portfolio

6.11.5 AbbVie Recent Developments/Updates

6.12 Gilead Sciences

6.12.1 Gilead Sciences Corporation Information

6.12.2 Gilead Sciences Cancer Immunotherapies Description and Business Overview

6.12.3 Gilead Sciences Cancer Immunotherapies Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Gilead Sciences Cancer Immunotherapies Product Portfolio

6.12.5 Gilead Sciences Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Cancer Immunotherapies Industry Chain Analysis

7.2 Cancer Immunotherapies Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Cancer Immunotherapies Production Mode & Process

7.4 Cancer Immunotherapies Sales and Marketing

7.4.1 Cancer Immunotherapies Sales Channels

7.4.2 Cancer Immunotherapies Distributors

7.5 Cancer Immunotherapies Customers

8 Cancer Immunotherapies Market Dynamics

8.1 Cancer Immunotherapies Industry Trends

8.2 Cancer Immunotherapies Market Drivers

8.3 Cancer Immunotherapies Market Challenges

8.4 Cancer Immunotherapies Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

ARMO BioSciences (Eli Lilly)

List of Tables

Table 1. Global Cancer Immunotherapies Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Cancer Immunotherapies Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Cancer Immunotherapies Market Competitive Situation by Manufacturers in 2023

Table 4. Global Cancer Immunotherapies Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Cancer Immunotherapies Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Cancer Immunotherapies Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Cancer Immunotherapies Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Cancer Immunotherapies Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Cancer Immunotherapies, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Cancer Immunotherapies, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Cancer Immunotherapies, Product Type & Application

Table 12. Global Key Manufacturers of Cancer Immunotherapies, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Cancer Immunotherapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapies as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Cancer Immunotherapies Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Cancer Immunotherapies Sales by Region (2019-2024) & (K Units)

Table 18. Global Cancer Immunotherapies Sales Market Share by Region (2019-2024)

Table 19. Global Cancer Immunotherapies Sales by Region (2025-2030) & (K Units)

Table 20. Global Cancer Immunotherapies Sales Market Share by Region (2025-2030)

Table 21. Global Cancer Immunotherapies Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Cancer Immunotherapies Revenue Market Share by Region (2019-2024)

Table 23. Global Cancer Immunotherapies Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Cancer Immunotherapies Revenue Market Share by Region (2025-2030)

Table 25. North America Cancer Immunotherapies Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Cancer Immunotherapies Sales by Country (2019-2024) & (K Units)

Table 27. North America Cancer Immunotherapies Sales by Country (2025-2030) & (K Units)

Table 28. North America Cancer Immunotherapies Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Cancer Immunotherapies Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Cancer Immunotherapies Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Cancer Immunotherapies Sales by Country (2019-2024) & (K Units)

Table 32. Europe Cancer Immunotherapies Sales by Country (2025-2030) & (K Units)

Table 33. Europe Cancer Immunotherapies Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Cancer Immunotherapies Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Cancer Immunotherapies Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Cancer Immunotherapies Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Cancer Immunotherapies Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Cancer Immunotherapies Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Cancer Immunotherapies Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Cancer Immunotherapies Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Cancer Immunotherapies Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Cancer Immunotherapies Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Cancer Immunotherapies Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Cancer Immunotherapies Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Cancer Immunotherapies Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Cancer Immunotherapies Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Cancer Immunotherapies Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Cancer Immunotherapies Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Cancer Immunotherapies Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Cancer Immunotherapies Sales (K Units) by Type (2019-2024)

Table 51. Global Cancer Immunotherapies Sales (K Units) by Type (2025-2030)

Table 52. Global Cancer Immunotherapies Sales Market Share by Type (2019-2024)

Table 53. Global Cancer Immunotherapies Sales Market Share by Type (2025-2030)

Table 54. Global Cancer Immunotherapies Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Cancer Immunotherapies Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Cancer Immunotherapies Revenue Market Share by Type (2019-2024)

Table 57. Global Cancer Immunotherapies Revenue Market Share by Type (2025-2030)

Table 58. Global Cancer Immunotherapies Price (USD/Unit) by Type (2019-2024)

Table 59. Global Cancer Immunotherapies Price (USD/Unit) by Type (2025-2030)

Table 60. Global Cancer Immunotherapies Sales (K Units) by Application (2019-2024)

Table 61. Global Cancer Immunotherapies Sales (K Units) by Application (2025-2030)

Table 62. Global Cancer Immunotherapies Sales Market Share by Application (2019-2024)

Table 63. Global Cancer Immunotherapies Sales Market Share by Application (2025-2030)

Table 64. Global Cancer Immunotherapies Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Cancer Immunotherapies Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Cancer Immunotherapies Revenue Market Share by Application (2019-2024)

Table 67. Global Cancer Immunotherapies Revenue Market Share by Application (2025-2030)

Table 68. Global Cancer Immunotherapies Price (USD/Unit) by Application (2019-2024)

Table 69. Global Cancer Immunotherapies Price (USD/Unit) by Application (2025-2030)

Table 70. Amgen Corporation Information

Table 71. Amgen Description and Business Overview

Table 72. Amgen Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 73. Amgen Cancer Immunotherapies Product

Table 74. Amgen Recent Developments/Updates

Table 75. AstraZeneca Corporation Information

Table 76. AstraZeneca Description and Business Overview

Table 77. AstraZeneca Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 78. AstraZeneca Cancer Immunotherapies Product

Table 79. AstraZeneca Recent Developments/Updates

Table 80. Roche Corporation Information

Table 81. Roche Description and Business Overview

Table 82. Roche Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 83. Roche Cancer Immunotherapies Product

Table 84. Roche Recent Developments/Updates

Table 85. Bristol-Myers Squibb Corporation Information

Table 86. Bristol-Myers Squibb Description and Business Overview

Table 87. Bristol-Myers Squibb Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 88. Bristol-Myers Squibb Cancer Immunotherapies Product

Table 89. Bristol-Myers Squibb Recent Developments/Updates

Table 90. Bayer Corporation Information

Table 91. Bayer Description and Business Overview

Table 92. Bayer Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 93. Bayer Cancer Immunotherapies Product

Table 94. Bayer Recent Developments/Updates

Table 95. Merck Corporation Information

Table 96. Merck Description and Business Overview

Table 97. Merck Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 98. Merck Cancer Immunotherapies Product

Table 99. Merck Recent Developments/Updates

Table 100. ARMO BioSciences (Eli Lilly) Corporation Information

Table 101. ARMO BioSciences (Eli Lilly) Description and Business Overview

Table 102. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 103. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product

Table 104. ARMO BioSciences (Eli Lilly) Recent Developments/Updates

Table 105. Novartis Corporation Information

Table 106. Novartis Description and Business Overview

Table 107. Novartis Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 108. Novartis Cancer Immunotherapies Product

Table 109. Novartis Recent Developments/Updates

Table 110. Pfizer Corporation Information

Table 111. Pfizer Description and Business Overview

Table 112. Pfizer Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 113. Pfizer Cancer Immunotherapies Product

Table 114. Pfizer Recent Developments/Updates

Table 115. Johnson & Johnson Corporation Information

Table 116. Johnson & Johnson Description and Business Overview

Table 117. Johnson & Johnson Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 118. Johnson & Johnson Cancer Immunotherapies Product

Table 119. Johnson & Johnson Recent Developments/Updates

Table 120. AbbVie Corporation Information

Table 121. AbbVie Description and Business Overview

Table 122. AbbVie Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 123. AbbVie Cancer Immunotherapies Product

Table 124. AbbVie Recent Developments/Updates

Table 125. Gilead Sciences Corporation Information

Table 126. Gilead Sciences Description and Business Overview

Table 127. Gilead Sciences Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 128. Gilead Sciences Cancer Immunotherapies Product

Table 129. Gilead Sciences Recent Developments/Updates

Table 130. Key Raw Materials Lists

Table 131. Raw Materials Key Suppliers Lists

Table 132. Cancer Immunotherapies Distributors List

Table 133. Cancer Immunotherapies Customers List

Table 134. Cancer Immunotherapies Market Trends

Table 135. Cancer Immunotherapies Market Drivers

Table 136. Cancer Immunotherapies Market Challenges

Table 137. Cancer Immunotherapies Market Restraints

Table 138. Research Programs/Design for This Report

Table 139. Key Data Information from Secondary Sources

Table 140. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Cancer Immunotherapies

Figure 2. Global Cancer Immunotherapies Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Cancer Immunotherapies Market Share by Type in 2023 & 2030

Figure 4. Monoclonal Antibodies (MABs) Product Picture

Figure 5. Cancer Vaccines Product Picture

Figure 6. Immunomodulators Product Picture

Figure 7. Adoptive Cell transfer Product Picture

Figure 8. Checkpoint Inhibitors Product Picture

Figure 9. Global Cancer Immunotherapies Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 10. Global Cancer Immunotherapies Market Share by Application in 2023 & 2030

Figure 11. Breast Cancer

Figure 12. Leukemia

Figure 13. Lymphoma

Figure 14. Melanoma

Figure 15. Colorectal Cancer

Figure 16. Non-Small Cell Lung Cancer

Figure 17. Global Cancer Immunotherapies Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 18. Global Cancer Immunotherapies Market Size (2019-2030) & (US$ Million)

Figure 19. Global Cancer Immunotherapies Sales (2019-2030) & (K Units)

Figure 20. Global Cancer Immunotherapies Average Price (USD/Unit) & (2019-2030)

Figure 21. Cancer Immunotherapies Report Years Considered

Figure 22. Cancer Immunotherapies Sales Share by Manufacturers in 2023

Figure 23. Global Cancer Immunotherapies Revenue Share by Manufacturers in 2023

Figure 24. The Global 5 and 10 Largest Cancer Immunotherapies Players: Market Share by Revenue in 2023

Figure 25. Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 26. Global Cancer Immunotherapies Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 27. North America Cancer Immunotherapies Sales Market Share by Country (2019-2030)

Figure 28. North America Cancer Immunotherapies Revenue Market Share by Country (2019-2030)

Figure 29. U.S. Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Canada Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Europe Cancer Immunotherapies Sales Market Share by Country (2019-2030)

Figure 32. Europe Cancer Immunotherapies Revenue Market Share by Country (2019-2030)

Figure 33. Germany Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. France Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. U.K. Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Italy Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Russia Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. Asia Pacific Cancer Immunotherapies Sales Market Share by Region (2019-2030)

Figure 39. Asia Pacific Cancer Immunotherapies Revenue Market Share by Region (2019-2030)

Figure 40. China Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Japan Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. South Korea Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. India Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Australia Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Taiwan Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Indonesia Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Thailand Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Malaysia Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Philippines Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Latin America Cancer Immunotherapies Sales Market Share by Country (2019-2030)

Figure 51. Latin America Cancer Immunotherapies Revenue Market Share by Country (2019-2030)

Figure 52. Mexico Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Brazil Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Argentina Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 55. Middle East & Africa Cancer Immunotherapies Sales Market Share by Country (2019-2030)

Figure 56. Middle East & Africa Cancer Immunotherapies Revenue Market Share by Country (2019-2030)

Figure 57. Turkey Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 58. Saudi Arabia Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 59. U.A.E Cancer Immunotherapies Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 60. Global Sales Market Share of Cancer Immunotherapies by Type (2019-2030)

Figure 61. Global Revenue Market Share of Cancer Immunotherapies by Type (2019-2030)

Figure 62. Global Cancer Immunotherapies Price (USD/Unit) by Type (2019-2030)

Figure 63. Global Sales Market Share of Cancer Immunotherapies by Application (2019-2030)

Figure 64. Global Revenue Market Share of Cancer Immunotherapies by Application (2019-2030)

Figure 65. Global Cancer Immunotherapies Price (USD/Unit) by Application (2019-2030)

Figure 66. Cancer Immunotherapies Value Chain

Figure 67. Cancer Immunotherapies Production Process

Figure 68. Channels of Distribution (Direct Vs Distribution)

Figure 69. Distributors Profiles

Figure 70. Bottom-up and Top-down Approaches for This Report

Figure 71. Data Triangulation

Figure 72. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Colon Cancer Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-31C5944

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global CAR T-Cell Immunotherapy Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-10J13802

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Color Detection Sensors Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-6G9623

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Appendix Cancer Treatment Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-2H1312

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions